1. Sambrook P, Cooper C: Osteoporosis. Lancet 2006, 367:2010-2018. 2. Tajeu GS, Delzell E, Smith W, Arora T, Curtis JR, Saag KG, Morrisey MA, Yun H, Kilgore ML. Bone. Death, Debility, and Destitution Following Hip Fracture. J Gerontol A Biol Sci Med Sci. 2013 Jul 19. [Epub ahead of print] 3. Frost SA, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Excess mortality attributable to hip fracture: a relative survival analysis 2013; Sep;56(1):23-9. 4. Ioannidis G, Flahive J, Pickard L, Papaioannou A, Chapurlat RD, Saag KG, Silverman S, Anderson FA Jr, Gehlbach SH, Hooven FH, Boonen S, Compston JE, Cooper C, Díez-Perez A, Greenspan SL, Lacroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Sambrook PN, Siris ES, Watts NB, Adachi JD; GLOW Investigators. Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int 2013; 24 (1):59-67. 5. World Health Organization: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group (Technical report series 843) Geneva, Switzerland, World Health Organization, 1994. 6. Armas LA, Recker RR. Pathophysiology of osteoporosis: new mechanistic insights. Endocrinol Metab Clin North Am 2012;41(3):475-86. 7. Warriner AH, Saag KG. Osteoporosis diagnosis and medical treatment. Orthop Clin North Am 2013; 44(2):125-35. 8. Lobersztajn A, Trémollières F. Menopause and bone. J Gynecol Obstet Biol Reprod (Paris) 2012; 41(7 Suppl):F28-32. 1. 9. Varner JM. Osteoporosis: a silent disease. Ala Nurse. 2012; 39(3):10-1. 10. Abd Jalil MA, Shuid AN, Muhammad N. Role of medicinal plants and natural products on osteoporotic fracture healing. Evid Based Complement Alternat Med 2012; 2012: 714512. 11. Diab DL, Watts NB. Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes 2013; Oct 21 [Epub ahead of print]. 12. Hudec SM, Camacho PM. Secondary causes of osteoporosis. Endocr Pract. 2013; 19(1):120-8. 13. Cianferotti L, Brandi ML. Guidance for the diagnosis, prevention and therapy of osteoporosis in Italy. Clin Cases Miner Bone Metab 2012;9(3):170-8 14. Robling AG, Turner CH. Mechanical signaling for bone modeling and remodeling. Crit Rev Eukaryot Gene Expr. 2009;19(4):319-38. 15. Boyce BF, Rosenberg E, de Papp AE, Duong le T. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur J Clin Invest 2012;42(12):1332-41. 16. Nakahama K. Cellular communications in bone homeostasis and repair. Cell Mol Life Sci 2010; 67(23):4001-9. 17. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3 Suppl 3:S131. 18. Mackiewicz Z, Niklińska WE, Kowalewska J, Chyczewski L. Bone as a source of organism vitality and regeneration. Folia Histochem Cytobiol. 2011;49(4):558-69. 19. Schurman L, Bagur A, Claus-Hermberg H, Messina OD, Negri AL, Sánchez A, González C, Diehl M, Rey P, Gamba J, Chiarpenello J, Moggia MS, Mastaglia S. Guidelines for the diagnosis, prevention and treatment of osteoporosis, 2012. Medicina (B Aires). 2013;73(1):55-74. 20. Leslie WD, Schousboe JT. A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world. Curr Osteoporos Rep 2011;9(3):129-40. 21. Food and Drug Administration (FDA): preclinical and clinical evaluation of agents used in the prevention of treatment of postmenopausal osteoporosis, April 1994 22. Bone H. Development and Evaluation of New drugs for Osteoporosis. Cap 65, en Osteoporosis, Vol 2, Second Edition Academic Press, 2001, p 533 – 538 23. Committee for Proprietary Medicinal products (CPMP): Efficacy working party. Note for Guidance in involutional osteoporosis in women CPMP/EWP/552/95, 1999 24. National Institute of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. JAMA 2001, 285: 785 – 795. 25. Tormey SM, Malone CM, McDermott EW, et al. Current status of combined hormone replacement therapy in clinical practice. Clin Breast cancer 2006 Feb;6 Suppl 2:S51-S57 26. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000, Suppl 6: S2 – 17. 27. Seibel MJ. Biochemical markers of bone emodeling. Endocrinol Metab Clin N Am 2003, 32: 83-113. 28. Kitatani K, Nakatsuka K, Naka H, et al. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy. J Bone Miner Metab. 2003; 21:217-24. 29. Schuiling KD, Robinia K, Nye R. Osteoporosis update. J Midwifery Womens Health 2011;56(6):615-27. 30. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126(1):13-20. 31. Das S, Crockett JC. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther 2013;7:435-48. 32. Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis 2013;5(3):107-11. 33. Ganapathy N, Gokulnathan S, Balan N, Maheswaran T, Venkatesan. Bisphosphonates: An update. J Pharm Bioallied Sci 2012;4(Suppl 2):S410-3. 34. Hampson G, Fogelman I. Clinical role of bisphosphonate therapy. Int J Womens Health. 2012;4:455-69. 35. Mas R. D-003: A new substance with promising lipid modifying and pleiotropic effects for atherosclerosis management. Drugs of the Future 2004, 29: 773 – 786 36. Gámez R., Mendoza S, Más R. et al: Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res 2000, 61: 8-16 37. Mendoza S, Gámez R, Noa M et al: The effects of D-003 and policosanol on the lipid profile and endothelemia cells in normocholesterolemic rabbits: a head to head comparison. Curr Ther Res 2001, 62: 209-220 38. Mendoza S, Gamez R, Mas R et al. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits. Int J Tissue Reaction 2003, XXV: 81 – 90. 39. Gámez R, Mendoza S, Mas R et al. Comparison of the cholesterol-lowering effects and toxicity of D-003 and lovastatin on normocholes–erolemic rabbits Drugs R&D 2003, 4: 219 - 229. 40. Menéndez R, Mas R, Amor AM et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol Res 2001 44: 299-304 41. Menéndez R; Más R; Pérez J et al. Oral administration of D-003, a mixture of very long chain saturated fatty acids, prevents casein-induced endogenous hypercholesterolemia in rabbits. Can J Physiol Pharmacol 2003, 82: 22- 29. 42. Castaño G, Mas R, Fernández L et al: Assessment of the effects of D-003, a new antiplatelet and hypocholesterolemic compound on healthy volunteers: a Phase I Clinical Study. Drugs R&D 2002, 23: 193 – 203 43. Castaño, G, Menéndez R, Mas R et al: Effects of D-003 on lipid profile and lipid peroxidation in healthy volunteers Clin Drug Invest 2003, 23: 193 – 203 44. Castaño G, Mas R, Fernández L et al. Effects of D-003 (5 – 40 mg/day) on lipid profile of patients with Type II hypercholesterolemia: a Phase II clinical study. Clin Drug Invest 2003, 23: 789 – 802 45. Castaño G, Mas R, Fernández L, et al. A comparison of the effects of D-003 and policosanol (5 and 10 mg/d) in patients with Type II hypercholesterolemia: a randomized, double-blinded study. Drugs Exptl Clin Res 2005, XXX (Suppl), 31 – 44 46. Menéndez R, Mas R, Pérez Y et al: Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can J Physiol Pharmacol 2002, 80: 13 – 17 47. Pérez Y, Menéndez R, Mas R et al: Efectos de la administración oral de D-003 sobre la peroxidación lipídica “in vivo” e “in vitro” en hígados de ratas. Rev Cubana Farmacia 2002, 36 (Suppl 2), 80 – 85 48. Pérez Y, Mas R, González RM et al. Effects of D-003 and policosanol on in vivo lipid peroxidation in rats. Archeimettel 2008 49. Molina V, Arruzazabala ML, Carbajal D et al: Antithrombotic effects of D003. Pharmacol Res 2000, 42: 137-143 50. Molina V, Carbajal D, Arruzazabala ML, Mas R. Effect of D-003 on intravascular platelet aggregation induced with collagen in rats. J Med Food 2004 51. Molina V, Arruzazabala ML, Carbajal D, Mas R: D-003, a new compound with effects on arachidonic acid metabolites. Prostagl, Leuktr, Ess Fatty Acids 2002, 67: 19 – 24 52. Arruzazabala ML, Carbajal D, Mas R et al: Effects of D-003, a new compound purified from sugar cane wax, on platelet aggregation in healthy volunteers: A randomized, double-blinded clinical study. Clin Drug Invest 2002, 23: 107 – 118 53. Arruzazabala ML, Molina V, Carbajal D, et al. Effects of D-003, a mixture of very long chain fatty acids purified from sugar cane wax, at 5 and 10 mg/d on platelet aggregation in healthy volunteers Int J Phamacol Clin Res 2005, 25: 29 – 39 54. Arruzazabala ML, Molina V, Carbajal D et al. Effects of D-003, a new substance purified from sugar cane wax, on platelet aggregation and plasma levels of arachidonic acid metabolites in healthy volunteers. Int J Pharmacol Clin Res 2004, 24: 56 – 64 55. Arruzazabala ML, Molina V, López E, et al. Effects of sugarcane wax acids on platelet aggregation in hypercholesterolemic patients: a dose-titration, randomised, placebo-controlled trial. Arzn-Forsch Drug Res 2008 (en prensa) 56. Molina V; Noa M; Arruzazabala ML; et al. Effect of D-003, a mixture of very long chain aliphatic acids purified from sugarcane wax, on cerebral ischemia in mongolian gerbils. J Med Food 2005 57. Molina V, Arruzazabala ML, Carbajal D, Mas R: Synergistic effect of D-003 and aspirin on experimental thrombosis model. Prostagl, Leukotr & Ess Fatty Acids 2003, 305 – 310 58. Carbajal D, Noa M, Molina V et al. Effect of D-003 on isoproterenol-induced myocardial necrosis in rats. J Med Food 2003, 6: 13 - 18s 59. Carbajal D, Arruzazabala ML, Noa M et al. Protective effect of D-003 on experimental spinal cord ischemia in rabbits. Prostagl, Leukotr & Ess Fatty Acids 2004 70: 1 –6 60. Carbajal D, Noa M, Molina V, et al. Effect of D-003 on sub-convulsive dose of kainic acid in rats. Drug R &D 2004. 61. Noa M., Mendoza S., Más R., Mendoza N. Effect of D-003, a mixture of high molecular weight primary acids from sugar cane wax, on CL4C-induced liver acute injury in rats. Drugs Exp Clin Res 2002, 28: 177-183. 62. Mendoza S, Noa M, Mas R, Mendoza N. Effect of D-003, a mixture of high molecular weight primary acids from sugar cane wax, on liver damage induced by paracetamol in rats. Int J Tissue Reaction 2003, 25: 91-98. 63. Noa M, Mendoza S, Mas R. Lack of protective effect of D003, a mixture of high molecular weight primary acids from sugar cane wax, on liver damage induced by galactosamine in rats. J Med Food 2005, 8: 343-347. 64. Noa M., Más R., Mendoza S, et al. Effects of D-003, a mixture of high molecular weight aliphatic acids from sugar cane wax, on bones from ovariectomized rats. Drugs Exptl Clin Res 2004, 30: 35 – 41. 65. Mendoza S, Noa M, Más R, Mendoza N. Effects of D-003 (5 – 200 mg/kg), a mixture of high molecular weight aliphatic acids from sugarcane wax, on bones and bone cell apoptosis in ovariectomized rats. Int J Tiss React 2005, XXVII: 213-222. 66. Mendoza S, Noa M, Mas R. A comparison of the effects of D-003, a mixture of high molecular weight aliphatic acids from sugarcane wax, and pravastatin, on bones and osteoclast apoptosis of ovariectomized rats. Drugs Exp Clin Res 2005, 31: 181-191. 67. Noa M, Mendoza S, Más R, et al. Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague Dawley rats. Drugs R D 2004; 5 : 281-290 68. Noa M, Mendoza S, Mas R, et al. Long term effects of D-003, a mixture of high molecular weight acids from sugarcane wax, on bones of ovariectomized rats: a one year study.- Die Pharmazie 2008 (en prensa) 69. Ceballos A., Mas R., Castaño G., et al. The effect of D-003 (10 mg/day) on biochemical parameters of bone remodelling in postmenopausal women: a randomized, double-blind study. Int J Clin Pharmacol Res. 2005; 25: 175-186 70. Ceballos A, Castaño G, Mendoza S, González J, Mas R, Fernández L, Illnait J, Mesa M, Gámez R, Fernández JC, Telles R, Marrero D, Gómez M, Ruiz D, Jardines Y Effect of D-003 (10 mg/day) on the bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study. Korean J Intern Med. 2011; 26: 168–178. 71. Ceballos A, Illnait J, Fernández JC, Mendoza S, Fernández L, Mas R, Gámez R, Mesa M, Cruz Y. Efectos del D-003 sobre la calidad de vida en mujeres postmenopáusicas con riesgo de osteoporosis de moderado a alto. Investigaciones Medicoquirúrgicas 2013;5(1):25-43. 72. Gámez R, Más R, Noa M et al: Acute and subchronic oral toxicity of D-00– in rats. Toxicol Letters 2000, 118: 31 - 41. 73. Gámez R, Mas R, Noa M et al. Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats. Drugs in R&D 2002, 3: 375 – 386. 74. Gámez R, Más R, Noa M et al: Effects of chronic administration of D-003, a mixture of sugar cane wax high molecular weight acids, in beagle–dogs. Drugs Exp & Clin Res 2004, 30: 75 – 88. 75. Gámez R, González JE, Rodeiro I et al. In vivo genotoxic evaluation of D-003, a mixture of very long chain aliphatic alcohols. J Med Food 2001, 4: 85-92. 76. Gámez R, Rodeiro I, Fernández I, Acosta P. Preliminary evaluation of the cytotoxic and genotoxic potential of D-003: A mixture of very long chain fatty acids. Teratog, Carcinog, Mutagenesis 2002, 22: 175 – 181 77. Rodríguez MD, Gámez R, González JE et al. Lack of developmental toxicity of D-003: a mixture of long-chain fatty acids in rats. Fd Chem Toxicol 2003, 41: 89 – 93. 78. Rodríguez MD, González JE, Aleman C et al. Evaluation of the reproductive and developmental toxicity of D-003, a mixture of long-chain fatty acids, in rats and–rabbits. Fd Chem Toxicol 2004, 42: 1977 - 1985. 79. Rodríguez MD, Gutiérrez A, Marrero G, García H. Perinatal/postnatal study of D-003, a mixture of long-chain fatty acids in rats. J Med Food 2006, 9: 223 – 230 80. Gámez R, Noa M, Mas R, et al. Long-term carcinogenicity of D-003, a mixture of high molecular weight acids from sugarcane wax, in Sprague Dawley rats: a 24 months study. Food Chem Tox 2007, 45:2352-2358 81. Arruzazabala ML, Carbajal D, Mas R et al: Effects of D-003, a new compound purified from sugar cane wax, on platelet aggregation in healthy volunteers: A randomized, double-blinded clinical study. Clin Drug Invest 2002, 23: 107 – 118 82. Arruzazabala ML, Molina V, Carbajal D, et al. Effects of D-003, a mixture of very long chain fatty acids purified from sugar cane wax, at 5 and 10 mg/d on platelet aggregation in healthy volunteers Int J Phamacol Clin Res 2005, 25: 29 – 39 83. Arruzazabala ML, Molina V, Carbajal D et al. Effects of D-003, a new substance purified from sugar cane wax, on platelet aggregation and plasma levels of arachidonic acid metabolites in healthy volunteers. Int J Pharmacol Clin Res 2004, 24: 56 – 64 84. Arruzazabala ML., Molina V., López E., Castaño G., Fernández L, Carbajal D., Mas R., Illnait J., Mendoza S., Ramírez Y, Effects of D-003, a mixture of sugarcane wax acids, on platelet aggregation in hypercholesterolemic patients: a dose-titration, randomised, placebo-controlled trial. Arzn- Forsch Drug Res 2008, 58): 376- 384. 85. Castaño G, Mas R, Fernández L, Illnait J, Mendoza S, Gámez R; Fernández J, Mesa M. A comparison of the effects of D-003 and policosanol (5 and 10 mg/d) in patients with Type II hypercholesterolemia: a randomized, double-blinded study. Drugs Exp Clin Res 2005, 31(Suppl): 31-44. 86. Arruzazabala ML, López E, Molina V, Illnait J, Carbajal D, Mas R, Fernández L, Fernández JC, Gámez R, Ravelo Y, Mesa M, Mendoza S, Ruiz D, Jardines Y. Efectos del D-003, una mezcla de ácidos grados de la caña de azúcar, sobre el perfil lipídico y la agregación plaquetaria de pacientes con diabetes tipo 2. Un ensayo controlado con placebo. Acta Bioq Clin Lat 2010;44(1): 15-24. 87. Vanek C, Connor WE. Do n-3 fatty acids prevent osteoporosis? Am J Clin Nutr. 2007;85(3):647-8. 88. Weiss LA, Barrett-Connor E, von Mühlen D. Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo Study. Am J Clin Nutr 2005;81(4):934-8. 89. Högström M, Nordström P, Nordström A. n-3 Fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO2 Study. Am J Clin Nutr 2007;85(3):803-7. 90. Griel AE, Kris-Etherton PM, Hilpert KF, Zhao G, West SG, Corwin RL. An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans. Nutr J 2007;16;6:2. 91. Orchard TS, Cauley JA, Frank GC, Neuhouser ML, Robinson JG, Snetselaar L, Tylavsky F, Wactawski-Wende J, Young AM, Lu B, Jackson RD. Fatty acid consumption and risk of fracture in the Women's Health Initiative. Am J Clin Nutr. 2010;92(6):1452-60. 92. Farina EK, Kiel DP, Roubenoff R, Schaefer EJ, Cupples LA, Tucker KL. Protective effects of fish intake and interactive effects of long-chain polyunsaturated fatty acid intakes on hip bone mineral density in older adults: the Framingham Osteoporosis Study. Am J Clin Nutr. 2011;93(5):1142-51. 93. Requerimientos para la notificacion y el reporte de Eventos Adversos Graves e Inesperados en los ensayos clínicos. Regulación No. 45-2007, Centro para el Control Estatal de los Medicamentos, Equipos y Dispositivos Médicos, MINSAP, La Habana, Cuba, 2007 94. Lips P, Leplege A. Development and validation of a quality of life questionnaire for patients with vertebral fractures: Qualeffo-41. Quality of Life Res 2000, 9: Suppl 6, 2000, 763-766 95. Friedewald W.T., Levy R.I, Friederickson S.D. (1972): Estimation of the concentration of low-density.lipoprotein cholesterol in plasma without of the preparative ultracentrifuge. Clin. Chem. 18: 499-502 96. O’Brien PC, Shampo MA: Statistical considerations for performing multiple tests in a single experiment. Comparing two therapies with respect to several endpoints. Mayo Clin Proc 1988 63:1140–1143.